Prostacyclin directed differentiation of cardiomyocytes from human embryonic stem cells
US8318489B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Dec 22, 2006 |
| Grant date | Nov 27, 2012 |
| Priority date | — |
| Expiry date | Oct 14, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as SB203580 and protein growth factors of the FGF, IGF and BMP families such as but not limited to IGF1, FGF2, BMP2, BMP4 and BMP6. and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from stem cells is also provided wherein the media contains these factors. The use of cardiomyocytes and cardiac progenitors produced by the directed differentiation in transplantation and screening for cardiac compounds is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.